Viewpoint Molecular Targeting, a radiopharmaceutical company based in Coralville, last week announced the successful completion of a merger with medical technology company Isoray.
Coralville, Iowa-based Viewpoint and Richland, Washington-based Isoray announced their intent to merge back in September. Having completed the merger, the combined company now has access to Isoray’s radioactive isotope, cesium-131, which is used in brachytherapy seeds to deliver radiation to certain solid cancers.
As part of the merger, the new company has adopted the name Perspective Therapeutics.
“The merger of Isoray and Viewpoint represents a powerful combination of two complementary businesses in the field of radiopharmaceuticals,” said Viewpoint CEO Thijs Spoor. “The mission of the combined company is to further develop the role of Cesium-131 for the treatment of a variety of cancers while we expand on our exciting and novel pipeline of proprietary targeting peptides to diagnose tumors in order to deliver powerful Targeted Alpha Therapies.”
As part of the deal, former Viewpoint CEO Thijs Spoor is chief executive and former Isoray CEO Lori Woods is chair of the board of directors of the merged company.